CurrentBlue Cross Blue Shield - MainePolicy 04-302

Local Delivery of Chemotherapeutic Agents/Antimicrobial Agents

Customize your policy alerts

Sign up for Blue Cross Blue Shield - Maine Policy 04-302 alerts

Get alerted when Policy 04-302 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Guidance on when local delivery of chemotherapeutic or antimicrobial agents (LDCA/LDAA) is appropriate as adjunctive therapy for periodontal disease management, affecting dental providers treating periodontitis for Blue Cross Blue Shield - Maine members.

Policy Summary

PayerBlue Cross Blue Shield - Maine

PolicyLocal Delivery of Chemotherapeutic Agents/Antimicrobial Agents

Policy CodePolicy 04-302

Change TypeNo material changes

Effective Date

Last ReviewOct 28, 2024

Next Review DateJan 1, 2025

Key ActionEnsure a current (within 12 months) dated 6-point periodontal charting is documented before applying LDCA/LDAA.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

>=5 mmmin pocket depth

6 weeks–6 monthswait after SRP

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentBlue Cross Blue Shield - MainePolicy 04-302

Local Delivery of Chemotherapeutic Agents/Antimicrobial Agents

Customize your policy alerts

Sign up for Blue Cross Blue Shield - Maine Policy 04-302 alerts

Get alerted when Policy 04-302 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerBlue Cross Blue Shield - Maine

PolicyLocal Delivery of Chemotherapeutic Agents/Antimicrobial Agents

Policy CodePolicy 04-302

Change TypeNo material changes

Effective Date

Last ReviewOct 28, 2024

Next Review DateJan 1, 2025

Key ActionEnsure a current (within 12 months) dated 6-point periodontal charting is documented before applying LDCA/LDAA.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

>=5 mmmin pocket depth

6 weeks–6 monthswait after SRP

D4381, D4341, D4342, D4346, D4910, D4999, D6081CDT codes

Coverage Criteria for Local Delivery Agents

inv-01: Appropriate use criteria for LDCA/LDAA

Covered when ALL of the following are met

Prerequisite therapy: Definitive non-surgical and/or surgical periodontal treatment (including scaling and root planing) has been completed and allowed time to heal.6 weeks to 6 months post SRP or surgery

LDCA/LDAA are adjunctive after SRP/surgery

Target site characteristics: Site demonstrates active/refractory disease: periodontal pocket measuring 5 mm or greater with spontaneous bleeding, bleeding on probing, or suppuration, and history of increasing pocket depth with associated attachment loss.>= 5 mm

Isolated refractory sites at maintenance appointments are included

Site distribution: Localized or isolated refractory sites (appropriate as adjunctive or during maintenance); not intended for generalized periodontitis where more extensive or surgical therapies may be required.

Generalized periodontitis should prompt consideration of comprehensive/surgical therapy

Documentation: A current (within 12 months), dated, post-periodontal maintenance and/or post-periodontal surgery 6-point periodontal charting is required.within 12 months

Use in medically compromised patients requires additional physician documentation and case-by-case review

Treatment limitations: LDCA/LDAA are not appropriate for use to regenerate alveolar bone; such application is considered experimental and investigational and is excluded.

Only natural teeth with favorable periodontal outcomes will be considered for benefit

The plan excludes the use of local delivery chemotherapeutic/antimicrobial agents (LDCA/LDAA) for applications that are not supported by clinical evidence. Specifically, LDCA/LDAA are considered experimental and investigational for regeneration of alveolar bone and therefore are not covered. Additionally, LDCA/LDAA are not appropriate for periodontal probing depths < 5 mm, and when a generalized pattern of periodontitis is present, more comprehensive or surgical therapies should be considered rather than localized LDCA/LDAA.

Application of LDCA/LDAA for alveolar bone regeneration is explicitly considered experimental and investigational by the plan because these products have not been clinically tested for that purpose; accordingly, such use is not medically necessary and is excluded from coverage.

Codes and Key Clinical Thresholds

CDT codes referencedCPT

D4381	Localized delivery of antimicrobial agents via a controlled release vehicle into diseased crevicular tissue per tooth
D4341	Periodontal scaling and root planing, four or more teeth per quadrant
D4342	Periodontal scaling and root planing, one to three teeth per quadrant
D4346	Scaling in the presence of generalized moderate or severe gingival inflammation full mouth, after oral exam
D4910	Periodontal maintenance
D4999	Unspecified periodontal procedure, by report
D6081	Scaling and debridement in the presence of inflammation or mucositis of a single implant, including cleaning of the implant surfaces, without flap entry and closure.

Periodontal probing depth — clinical threshold for consideration

Clinical thresholdPeriodontal probing depth >= 5 mm

Associated signsPersistent inflammation, spontaneous bleeding or bleeding on probing, or suppuration

Context for useConsider after completion of definitive non-surgical and/or surgical periodontal treatment

Maintenance settingAlso indicated for isolated refractory sites diagnosed at periodontal maintenance appointments

Provider Requirements, Documentation, and Billing Notes

Prior Authorization

Code listing (informational) — verify PA and member benefits

The following CDT/diagnosis codes are provided for informational purposes only. Inclusion does not guarantee member coverage or provider reimbursement — verify the member's contract and prior authorization requirements prior to providing services.

CDT: D4381 Localized delivery of antimicrobial agents via a controlled release vehicle into diseased crevicular tissue per tooth
CDT: D4341 Periodontal scaling and root planing, four or more teeth per quadrant
CDT: D4342 Periodontal scaling and root planing, one to three teeth per quadrant
CDT: D4346 Scaling in the presence of generalized moderate or severe gingival inflammation, full mouth, after oral exam
CDT: D4910 Periodontal maintenance
CDT: D4999 Unspecified periodontal procedure, by report
CDT: D6081 Scaling and debridement in the presence of inflammation or mucositis of a single implant, including cleaning of the implant surfaces, without flap entry and closure
ICD-10-CM: See current CDT code book for applicable dental diagnosis codes

Background and Clinical Context

Scaling and root planing (SRP) is the standard non-surgical therapy for chronic periodontitis and is highly effective; most periodontal sites respond to SRP and do not require local antimicrobial adjuncts. Local delivery agents are intended for refractory or localized recurrent periodontal pockets—used as an adjunct after definitive non-surgical or surgical therapy—and not as first-line therapy.

Definitions and Terminology

Refractory disease sites — definition including pocketing >=5 mm with persistent signs

DefinitionSites with periodontal pocketing >= 5 mm with persistent signs of inflammation, spontaneous bleeding or bleeding on probing, suppuration and/or increasing loss of clinical attachment

TimingEvaluation is made following completion of definitive non-surgical and/or surgical periodontal treatment

Inclusion at maintenanceIsolated refractory sites at periodontal maintenance appointments are included

D4381 — definition for localized delivery of antimicrobial agents (CDT code)

CDT codeD4381

Short descriptionLocalized delivery of antimicrobial agents via a controlled release vehicle into diseased crevicular tissue per tooth

Policy Summary

PayerBlue Cross Blue Shield - Maine

PolicyLocal Delivery of Chemotherapeutic Agents/Antimicrobial Agents

Policy CodePolicy 04-302

Change TypeNo material changes

Effective Date

Last ReviewOct 28, 2024

Next Review DateJan 1, 2025

Key ActionEnsure a current (within 12 months) dated 6-point periodontal charting is documented before applying LDCA/LDAA.

SourceLink

On This Page

Note

Adjunctive use after SRP — timing and clinical context

LDCA/LDAA modalities are adjunctive therapies and are considered only after definitive non-surgical therapy (scaling and root planing) has been performed and allowed time to heal. Allow adequate healing time before adjunctive local delivery: typically 6 weeks to 6 months after scaling and root planing or periodontal surgery.

Adjunctive timing: perform 6 weeks to 6 months post scaling and root planing or periodontal surgery
LDCA/LDAA are for pockets ≥5 mm with signs of active/refractory disease (spontaneous bleeding, bleeding on probing, suppuration, or documented increasing pocket depth/attachment loss)
If multiple recurrent/residual inflammatory sites persist after SRP, consider more extensive periodontal modalities (including surgical options) rather than repeat adjunctive LDCA/LDAA

Documentation Required

Required documentation — 6-point periodontal charting

Documented periodontal assessment is required for review and payment. Maintain current periodontal charting and supporting clinical documentation.

A current (within 12 months), dated 6-point periodontal charting is required (post periodontal maintenance and/or post-periodontal surgery as applicable)
Include documentation of treated sites, pocket depths, bleeding on probing, suppuration, and rationale for local antimicrobial delivery
Only natural teeth with favorable periodontal outcomes will be considered for benefit

Documentation Required

Medically compromised patients — case-by-case review

Use of LDCA/LDAA in medically compromised patients will be reviewed on a case-by-case basis and requires supporting physician documentation.

Submit physician documentation describing the medical condition and justification for local antimicrobial therapy
Coverage for medically compromised patients is not automatic; benefits will be determined after clinical review

Denial Risk

Bundled denial risk — related services may be denied

When services are performed in conjunction with or in preparation for a non-covered or denied service, related services may also be denied. Verify coverage for all associated procedures before billing.

If SRP or another foundational therapy is non-covered or denied, adjunctive LDCA/LDAA services tied to that therapy may also be denied
Confirm member benefits and any required prior authorization for both primary and adjunctive procedures

Use noteListed for informational purposes; inclusion does not guarantee coverage — verify member contract for coverage and prior authorization requirements